Used as an intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. It serves as a key building block in creating targeted covalent inhibitors due to the presence of the reactive bromoacetyl group, which can form stable bonds with cysteine residues in specific enzymes. Commonly employed in medicinal chemistry for structure-activity relationship studies and in the preparation of proteolysis-targeting chimeras (PROTACs). Also utilized in research settings for labeling and conjugation in biochemical assays.